OGN
NYSEOrganon & Co
$8.83
+1.92 (+27.79%)
2026-04-10 00:00
Healthcare
Drug Manufacturers - General
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$1.57B
P/E Ratio
8.4
52W Low
52W High
$5.69
$11.29
Volume
38.1M
Analyst Rating
Hold
Target: $9
4 Analyst Ratings
Strong Buy
0
Buy
0
Hold
4
Sell
0
Price Target Range
Low: $9
Avg: $9
High: $9
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily ...
Employees
10,000
Website
organon.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $6.22B | 20.7% | $187.0M | $862.0M |
| 2024 | $6.40B | 23.2% | $864.0M | $1.29B |
| 2023 | $6.26B | 21.2% | $1.02B | $1.06B |
| 2022 | $6.17B | 27.6% | $917.0M | $1.28B |
| 2021 | $6.30B | 30.4% | $1.35B | $2.95B |
| 2025 Q4 | $1.51B | 15.6% | -$205.0M | $186.0M |
| 2025 Q3 | $1.60B | 22.3% | $160.0M | $379.0M |
| 2025 Q2 | $1.59B | 20.5% | $145.0M | $259.0M |
| 2025 Q1 | $1.51B | 21.5% | $87.0M | $172.0M |
| 2024 Q4 | $1.59B | 18.6% | $109.0M | $522.0M |
| 2024 Q3 | $1.58B | 24.7% | $359.0M | $217.0M |
| 2024 Q2 | $1.61B | 24.0% | $195.0M | $364.0M |
| 2024 Q1 | $1.62B | 25.5% | $201.0M | $172.0M |